Common Mental Health Issues in Patients with HIV

1. Common Mental Health Issues in Patients with HIV Francisco Fernandez, MD Professor and Chair, USF Health Psychiatry USF Morsani College of Medicine Faculty, Florida/Caribbean AETC

2. Disclosure of Financial Relationships This speaker has no significant financial relationships with commercial entities to disclose. This speaker will discuss off-label use or an investigational product during the program: • Use of stimulants and amantadine in cognitive disorders. This slide set has been peer-reviewed to ensure that there are no conflicts of interest represented in the presentation.

3. Psychiatric Illness in HIV • Mental disorders are highly prevalent in HIV-1 infection and AIDS • Dual Diagnosis  coexisting substance abuse and psychiatric disorders • Triple Diagnosis  coexisting medical illness with substance abuse and psychiatric disorders • HIV-Associated Neurocognitive Disorders (HAND)

4. DEPRESSION

5. Epidemiology of Depression in HIV • Depression is the most common mental health disorder in HIV patients1 • 36% of adults patients receiving medical care for HIV were depressed in the past 12 months2 • Depression is the most common reason for psychiatric referral • Rates of depression are highest among injection drug users (IDU) and women engaging in high risk behaviors3 Orlando et al., 2002; Komiti et al., 2003 HCSUS Bing et al., 2001;Galvan et al., 2002 3. Goodkin et al., 1996

6. HIV Mood Disorders: Completed Suicide Study Subjects Findings ________________________________________________________ Marzuk 1992 AIDS vs others 36-66 x increase with AIDS Kizer 1992 AIDS vs others 17 x increase with AIDS Cote 1992 72,000 U.S. suicides 7.4 x increase with AIDS Marzuk 1997 HIV+ vs others 2-3 x increase with HIV < suicide risk factors (RFs)

7. Types of Depressive Disorders vs Major Depressive Disorder (MDD) • Psychiatric Differential Diagnoses • Mild depression (or minor depression) • Dysthymia • Bipolar disorder, currently depressed • Adjustment disorder with depressed mood • Medical Differential Diagnoses • Central Nervous System (CNS) HIV cognitive disorders [Minor Cognitive Motor Disorder (MCMD) & HIV-associated dementia (HAD)] • CNS opportunistic illnesses and cancers • Substance abuse • Medication effects • Endocrine abnormalities (hypogonadism, adrenal insufficiency)

8. How to Identify MDD in a Primary Care Setting? • Fewer than 50% of patients with MDD are identified by their primary care providers (PCPs)1 • Two simple questions to ask: 1. During the past two weeks have you felt sad, down or depressed most of the day, nearly every day? 2. During the past two weeks have you been less interested in most things or less able to enjoy the things that you used to enjoy most of the time? 1. Asch et al., 2003

9. Screening and Diagnostic Tools • Screening: PHQ-2 • Diagnosis: PHQ-9; Depressive disorder module of the SCID or MINI-6 • PHQ-2 and PHQ-9 readily available at no cost • PHQ-9 reliable diagnostic tool. Also provides severity parameters which can help decide the action plan PHQ-2: Patient Health Questionaire-2 Kroenke et al. Med Care 2003; 41(11):1284-92 PHQ-9:Patient Health Questionaire-9 Kroenke et al. J GenIntern Med, 2001;16(9)606-13 SCID: Structured Clinical Interview for DSM Disorders www.cumc.columbia.edu/dept/scid/index.html MINI-6: The Mini-International Neuropyschiatric Interview www.medical-outcomes.com

10. First Line Treatment for MDD • Psychotherapies: “talk therapy” like cognitive behavioral therapy (CBT), interpersonal therapy (IT), psychodynamic therapy, etc. • Medications: antidepressants [selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), others] • Neurostimulation • Electroconvulsive therapy (ECT) • Transcranial Magnetic Stimulation • Combination of psychotherapy and medication

11. Selecting an Antidepressant: Potential for Drug-Drug Interactions Low P450 blockers:Likely to have little impact on metabolism of other drugs Potent P450 blockers: Potential for strong impact on metabolism of other drugs Crewe HK, et al. Br J ClinPharmacol. 1992;34:262-265. Nemeroff CB, et al. Am J Psychiatry. 1996;153:311-320. von Moltke LL, et al. J ClinPsychopharmacol. 1994;14:1-4. von Motkle LL, et al. ClinPharmacokinet. 1995;20(suppl 1):33.

12. When to Refer to a Mental Health Specialist • Acute risk of suicide • Psychotic symptoms, signs of dementia or bipolar disorder • Patients with limited or non-response to treatment • PCP level of comfort

13. ANXIETY

14. Prevalence of Anxiety • Anxiety disorders are the most prevalent psychiatric disorders in the general population (Lifetime prevalence 25%)1 • In HIV infected individuals the prevalence rate of anxiety disorders can be as high as 38%2 • Cohen et al. (2001) found that in an urban U.S. HIV clinic anxiety was present in up to 70% of patients Kessler et al., 1994, 2005 Elliott, 1998

15. Anxiety in HIV Patients • Anxiety as a normal response • Anxiety as a disorder • Primary • Adjustment, panic disorder, post-traumatic stress disorder (PTSD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), obsessive compulsive disorder (OCD) • Secondary Anxiety • AIDS-associated illness, other medical illnesses • Anxiety as a side effect • Secondary to medications • like HIV or hepatitis C virus (HCV) treatments (e.g., efavirenz, steroids, isoniazid, interferon) • Secondary to street drugs (stimulants, alcohol, etc)

16. Screening and Diagnostic Tools • Screening: Hospital Depression and Anxiety Scale (HADS); Hamilton Anxiety Scale (HAM-A) • Diagnosis: Specific modules of the SCID or MINI-6; specific disorder scales • Screening questions

17. Treatment Approaches • Overall, very similar to major depressive disorder • Psychotherapies: “talk therapy” like CBT (cognitive behavioral therapy), IT (interpersonal therapy), psychodynamic therapy, support groups, etc. • Medications: antidepressants (SSRIs, SNRIs, TCAs, MAOIs, other), benzodiazepines. • In substance use disorders (SUD)  buspirone, antiepileptic drugs [(AEDs) tiagabine, gabapentin] • Combination of psychotherapy and medication

18. SUBSTANCE USE, ABUSE, DEPENDENCE

19. Prevalence of Substance Use Disorders (SUD) in HIV • SUD have a higher prevalence in HIV patients compared to the general population • Bidirectional risk relationship between HIV and SUD1,2,3,4 • Most prevalent: alcohol (EtOH), cocaine, opiates • 25-60% life time prevalence of alcohol abuse or dependence in HIV patients, a 2-4 fold increase compared to the general population 5,6,7,8 • 23-56 % lifetime prevalence of other drug use disorders in HIV subjects, a 4-5 fold increase compared to the general population 5,6,7,8 1. Harvey and Spigner, 1995; 2. Katz et al., 2000; 3. Stall and Purcell, 2000; 4. Wingoodand DiClemente, 1998; 5. Rabkin, 1996; 6. Dew et al., 1997; 7. Ferrandoet al., 1998; 8. Kessler et al., 1994

20. Impact of SUD on HIV • In the U.S., SUD is the main driver of HIV transmission [intravenous drugs (IVD) leading] • If untreated can result in poor treatment outcomes • Decreased adherence to combination antiretroviral therapy (CART) • Increased risk taking behaviors • Increased medical and psychiatric comorbidities

21. Recognizing SUD • High suspicion is recommended given high prevalence and bidirectional risk • Should be asked at initial visit and at each follow up • Use screening instruments • Use of urine drug screens (UDS) • Generally more effective to have an open/ nonjudgmental approach when asking patients • “Many persons who are ill may use drugs or alcohol to get through tough times. What have you used to cope with these difficult times?”

22. Treatment Options for SUD • Medical treatment • Detoxification – first step • Opiates methadone, buprenorphine, clonidine • Cocaine  symptomatic, dopamine (DA) agonists, naltrexone • ETOH  benzodiazepines, naltrexone • Nicotine  replacement therapy, bupropion, varenicline • Maintenance: methadone, buprenorphine, DA agonists, naltrexone, disulfiram, topiramate • Topiramate  signal across all appetitive drives • Therapeutic Strategies • Motivational enhancement therapy, CBT • 12 Steps facilitation [Alcoholics Anonymous (AA), Narcotics Anonymous (NA)] • Residential treatment

23. HIV Associated Neurocognitive Disorder (HAND) • HIV-neurocognitive impairment continues to be an important problem • HIV-neurocognitive impairment can be easily recognized • Neurodiagnostic tests can improve confidence in the diagnosis and exclude neoplasms and opportunistic infections • HIV-neurocognitive impairment can be treated • Primary therapy  antiretroviral therapy (ART) that better distributes into the CNS leads to better outcomes • Secondary anti-inflammatory therapies • Palliative therapies

24. Criteria for HAND

25. Changing Prevalence of HAND • Highly active antiretroviral therapy (HAART) • HIV-associated dementia (HAD) • Motor neuron disease (MND) • Asymptomatic neurocognitive impairment (ANI) Modified from Heaton R., et al: HIV-associated neurocognitive disorders (HAND) persist in the era of potent antiretroviral therapy: The CHARTER Study; and Heaton R., J IntNeuropsychol Soc. May 1995;1(3):231-251.

26. Screening for HAND by Self Report Medical Outcomes Study (MOS) HIV Cognitive Functional Status Scale 1. Difficulty reasoning and solving problems? 2. Forget things that happened recently? 3. Trouble keeping your attention on any activity for long? 4. Difficulty doing activities involving concentration and thinking? Validated against neuropsychological (NP) overall performance Knippels, Goodkin, Weiss, et al., AIDS, 2002;16:259-267

27. Pharmacotherapy of HAND • Primary Treatments • Antiretroviral medications • Secondary Treatments • Immunostimulants and inflammatory mediators • Palliative Treatments • Psychotropic agents • Nutritional

28. Neuro-AIDS Can Be Treated Higher CNS Penetration-Effectiveness (CPE) Scores and Lower Viral Loads in Cerebrospinal Fluid (CSF) Letendre et al, Archives of Neurology, 2008

29. Antiretroviral EffectivenessCNS Penetration-Effectiveness Score LeTendre S., et al, Arch Neurol., 2007 From JC McArthur, MBBS, MPH, at 13th Annual Ryan White HIV/AIDS Program Clinical Conference, IAS–USA.

30. Relevance of ART, CNS Penetrance & HAND • Despite HAART’s effect on incidence, prevalence of HAND remains high, and pathological evidence of CNS infection persists (Heaton R., Neurology, 2010; Vago L., AIDS, 2002) • HAART can reverse neurocognitive deficits, but at best, it is usually only partial • ? Functional performance change (TozziV., AIDS, 2002) • Long term aviremic HIV+ individuals have high rate of HAND  MND (SimioniP., AIDS 2009)

31. How Best To Treat HAND in 2012 • Primary therapy  suppress HIV RNA viral load systemically and in CSF • Consider secondary pharmacotherapy • Control all controllables • Anxiety and depression, drug and alcohol use • Co-infections (HCV) • Medication side-effects • Lab indices (anemia, thyroid, B12, glucose, cholesterol) • Trial of dopamine agonists • Stimulants • Amantadine

32. Summary • Depression, anxiety, SUD, HAND, and HIV are highly comorbid • Once they combine, there is synergy in the overall effect on the affected individuals and their treatments • Careful medical and neurobehavioral evaluation is required to rule out primary treatable CNS disease and comorbid psychiatric disorders • Effective treatment strategies are available for the primary and secondary HIV manifestations • The neuropsychiatric complications of the disease deserve the same aggressive approach as that of the systemic aspects of the disease

33. A Neuropsychiatric Case Study DANIEL

34. Daniel • Daniel is a 52-year-old man, HIV+ since 1996. He remains asymptomatic. He also has hepatitis C. • 1996: CD4=212, viral load (VL)=182,000 • 1997: HAART – undetectable VL; CD4 ~ 600's. • Drug holiday – 2004-06, resumed treatment 2007 • Current Meds: darunavir, etravirine, emtricitabine/tenofovir, ritonavir • High-level job, he is meticulous and dresses impeccably • He is a “weekend warrior” • Uses ecstasy and alcohol. • For the last 9 months  low energy and some memory difficulties • He thought this was stress-related; however, a vacation did not help

35. Daniel – What is your presumptive diagnosis? • Adjustment disorder • ART resistance • Substance abuse • Cirrhosis • Depression

36. What would you like to do next? • Cognitive assessment • Complete blood count (CBC), comprehensive metabolic panel (CMP), syphilis serology, CD4, viral load • Endocrine screen • CT-brain and/or MRI • All of the above

37. Daniel – Clinical & Lab Findings • h/o recurrent depressive illness • h/o relapsing alcoholism and ecstasy abuse • Liver enzymes and thyroid labs – within normal limits (wnl) • VL and CD4 - no changes • CT Scan - wnl • Testosterone – 120 ng/dl

38. What next? • Initiate low dose citalopram • Hormone replacement therapy (HRT) • PRN lorazepam • End of life Counseling • All of the above

39. Daniel – Recommendations • Treat alcohol / ecstasy abuse • HRT • No improvement with testosterone replacement in 4 to 6 weeks • Start formal psychotropic agent • Which would you choose?

40. Which psychotropic agent would you choose? • Citalopram (Celexa®) • Quetiapine (Seroquel®) • Venlafaxine (Effexor XR®) • Bupropion (WellbutrinXL®) • Topiramate (Topamax®)

41. Daniel – follow up • Daniel stops alcohol and ecstasy use temporarily • Testosterone replacement continues • Venlafaxine 150 mg/day • Initially his energy, memory and concentration improve • Complains of feeling depressed, hopeless, anhedonic, isolates himself, poor appetite, mild suicidal thoughts, interrupted sleep

42. What is your diagnosis now? • Adjustment disorder with depressed mood • Substance-induced mood disorder • Major depression – recurrent • Bipolar depression • Acute stress reaction/disorder

43. Daniel – MDD recurrent • SNRI (liver protection, low drug-drug interaction potential with ARVs, low CNS side effects) • Increase venlafaxine to 300 mg/daily • Daniel’s depression improves, but memory and concentration do not

44. What are his other diagnoses? • Residual depression • Relapse on alcohol and ecstasy • Minor cognitive-motor disorder • Acute stress disorder • Neurotoxicity

45. Daniel – 2 months later … • Daniel shows very late to his appointment – unusual for him • He looks unkempt • Seems distracted

46. What do we need to rule out? • Residual depression • Relapse on alcohol and ecstasy • HIV-Associated Dementia • Progression to AIDS • Neurotoxicity

47. Daniel 2 months later … • Alcohol? None • Ecstasy? None • Depression? No • Testosterone? Normal • Liver Function Tests (LFTs), Thyroid and HIV Labs – no changes

48. Now what? • Neuroimaging • Lumbar puncture • Neuropsychological testing • Psychiatric consultation • All of the above

49. Daniel – other considerations • Is Daniel taking other medications? • Other drugs? • Over the counter pills or vitamins? • Any new events? • None of these are present? • Now what?

50. Daniel – Work up results … • Lumbar Puncture? Mild pleocytosis and elevated protein. • Neuro consult “minor cognitive abnormalities without any focal neurological findings besides mild neuropathy." • Psychiatry “no residual depression, no active substance use, Mini-Mental State Exam (MMSE) 25/30, slowing of information processing” • Neuropsychological evaluation – attention and working memory deficits. Slow motor activity and thinking processes. • MRI – reported as normal • What does this mean? Diagnoses?